Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 25

Learn how the Galleri multi-cancer early detection test uses cfDNA methylation, what Cancer Signal Detected and No Cancer Signal Detected mean, and what current trials show about accuracy and follow-up.

Galleri Test: Multi-Cancer Early Detection, Cancer Signal, and Result Meaning

Learn how Guardant360 Liquid CDx analyzes ctDNA for cancer mutations, what the current FDA-approved panel reports, how companion-diagnostic findings guide therapy, and why negative plasma results may need tissue confirmation.

Guardant360 Test: Liquid Biopsy, Cancer Mutations, ctDNA, and Genomic Profiling

Understand what a KRAS liquid biopsy measures, how ctDNA results are interpreted, and what KRAS mutations can mean in colorectal, lung, and pancreatic cancer.

KRAS Liquid Biopsy Test: Colon, Lung, Pancreatic Cancer, Mutation Status, and...

Learn how liquid biopsy resistance mutation tests detect ctDNA markers of cancer drug resistance, when testing is useful, how results are read, and why negative results may need tissue confirmation.

Liquid Biopsy Resistance Mutation Test: Cancer Drug Resistance Markers and Mutation...

Learn how liquid biopsy tests use circulating tumor DNA for blood-based cancer profiling, mutation detection, treatment selection, resistance testing, MRD monitoring, and result interpretation.

Liquid Biopsy Test: Circulating Tumor DNA, Blood-Based Tumor Testing, and Mutation...

Learn how the OncoBEAM ctDNA test uses BEAMing digital PCR for sensitive mutation detection, RAS testing in metastatic colorectal cancer, resistance monitoring, and blood-based result interpretation.

OncoBEAM Test: ctDNA Mutation Testing, Digital PCR, and Blood-Based Monitoring

Learn how the RaDaR ctDNA test uses personalized tumor mutations to detect MRD, monitor recurrence risk, and interpret positive or negative results.

RaDaR Test: ctDNA MRD, Cancer Monitoring, and Recurrence Detection

Understand how the Signatera ctDNA test detects personalized MRD, what positive and negative results mean, and how serial testing may signal cancer recurrence.

Signatera Test: ctDNA MRD, Cancer Recurrence, and Personalized Monitoring

Learn what the Tempus xF liquid biopsy tests, how xF differs from xF+, and how to interpret ctDNA mutations, negative results, MSI-H, and bTMB.

Tempus xF Test: Liquid Biopsy, Cancer Genomics, ctDNA, and Mutation Results

Learn how tumor-informed ctDNA tests personalize MRD monitoring, what positive and negative results mean, and how they compare with tumor-naive blood testing.

Tumor-Informed ctDNA Test: Personalized MRD Monitoring, Recurrence Detection, and Result Meaning

Tumor-Naive ctDNA Test: Blood-Based Cancer Monitoring Without Tumor Tissue

Learn how ALK testing helps classify anaplastic large cell lymphoma, what positive IHC or ALK rearrangement results mean, and when FISH or molecular confirmation is used.

ALK Test for Anaplastic Large Cell Lymphoma: Fusion Marker, Positive Result,...

Understand BCL2 rearrangement testing in follicular lymphoma, including IGH::BCL2, t(14;18), FISH results, negative tests, and how findings affect tumor classification.

BCL2 Rearrangement Test: Follicular Lymphoma, Rearrangement Status, and FISH Result

Learn how BCR-ABL1 quantitative PCR monitors CML, including International Scale percentages, MMR, MR4/MR4.5, milestone timing, rising results, and undetectable transcripts.

BCR-ABL1 Quantitative PCR Test: CML Monitoring, Molecular Response, and Transcript Level

Learn how BCR-ABL1 testing detects the Philadelphia chromosome in CML, how PCR, FISH, and karyotyping differ, and what positive or negative results mean.

BCR-ABL1 Test: Chronic Myeloid Leukemia, Philadelphia Chromosome, and Molecular Diagnosis

Learn how beta-2 microglobulin is used in multiple myeloma staging and prognosis, why kidney function changes the result, and how to interpret high levels.

Beta-2 Microglobulin Test for Myeloma: Staging, Prognosis, Tumor Burden, and Kidney...

1...242526...137 Page 25 of 137